Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis

K. Suzuki; K. Sunami; K. Ohashi; S. Iida; T. Mori; H. Handa; K. Matsue; M. Miyoshi; E. Bleickardt; M. Matsumoto; M. Taniwaki

doi:10.1038/bcj.2017.18

Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis

K. Suzuki, K. Sunami, K. Ohashi, S. Iida, T. Mori, H. Handa, K. Matsue, M. Miyoshi, E. Bleickardt, M. Matsumoto, M. Taniwaki

Department of Internal Medicine (Hematology)

Research output: Contribution to journal › Letter › peer-review

12 Citations (Scopus)

Original language	English
Article number	e540
Journal	Blood cancer journal
Volume	7
Issue number	3
DOIs	https://doi.org/10.1038/bcj.2017.18
Publication status	Published - 2017 Mar 10

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1038/bcj.2017.18

Cite this

@article{20a43c18fba14065a77fef00386c8f7c,

title = "Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis",

author = "K. Suzuki and K. Sunami and K. Ohashi and S. Iida and T. Mori and H. Handa and K. Matsue and M. Miyoshi and E. Bleickardt and M. Matsumoto and M. Taniwaki",

year = "2017",

month = mar,

day = "10",

doi = "10.1038/bcj.2017.18",

language = "English",

volume = "7",

journal = "Blood cancer journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "3",

}

TY - JOUR

T1 - Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma

T2 - ELOQUENT-2 Japanese patient subanalysis

AU - Suzuki, K.

AU - Sunami, K.

AU - Ohashi, K.

AU - Iida, S.

AU - Mori, T.

AU - Handa, H.

AU - Matsue, K.

AU - Miyoshi, M.

AU - Bleickardt, E.

AU - Matsumoto, M.

AU - Taniwaki, M.

PY - 2017/3/10

Y1 - 2017/3/10

UR - http://www.scopus.com/inward/record.url?scp=85015231066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015231066&partnerID=8YFLogxK

U2 - 10.1038/bcj.2017.18

DO - 10.1038/bcj.2017.18

M3 - Letter

C2 - 28282035

AN - SCOPUS:85015231066

SN - 2044-5385

VL - 7

JO - Blood cancer journal

JF - Blood cancer journal

IS - 3

M1 - e540

ER -

Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this